|
gptkbp:instanceOf
|
gptkb:antidepressant
gptkb:selective_serotonin_reuptake_inhibitor
|
|
gptkbp:approvalYear
|
1991
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:N06AB06
|
|
gptkbp:availableGeneric
|
yes
|
|
gptkbp:availableOn
|
gptkb:tablet
oral concentrate
|
|
gptkbp:brand
|
gptkb:Lustral
gptkb:Zoloft
|
|
gptkbp:CASNumber
|
gptkb:79617-96-2
|
|
gptkbp:chemicalFormula
|
C17H17Cl2N
|
|
gptkbp:contraindication
|
concurrent use with MAO inhibitors
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:drugClass
|
SSRI
|
|
gptkbp:eliminationHalfLife
|
26 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:firstMarketedYear
|
1991
|
|
gptkbp:interactsWith
|
gptkb:warfarin
gptkb:MAO_inhibitors
gptkb:NSAIDs
gptkb:pimozide
other serotonergic drugs
antiplatelet drugs
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits reuptake of serotonin
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
306.23 g/mol
|
|
gptkbp:patentedYear
|
1978
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adults
children (OCD only)
|
|
gptkbp:riskOfDiscontinuationSyndrome
|
yes
|
|
gptkbp:riskOfSerotoninSyndrome
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:sexual_dysfunction
nausea
diarrhea
dizziness
insomnia
drowsiness
dry mouth
|
|
gptkbp:usedFor
|
gptkb:obsessive-compulsive_disorder
gptkb:panic_disorder
gptkb:post-traumatic_stress_disorder
gptkb:social_anxiety_disorder
gptkb:major_depressive_disorder
premenstrual dysphoric disorder
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:SLC6A4_protein
gptkb:CLC-21
gptkb:SSRIs
gptkb:CYP3A4
gptkb:Zoloft
gptkb:SPAN-B
gptkb:Selective_serotonin_reuptake_inhibitors
gptkb:selective_serotonin_reuptake_inhibitors
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
sertraline
|